Loralee A McMahon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Loralee A McMahon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ben Panepento
Allergy/Immunology & Rheumatology Division, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA
1 shared publication - Changyong Feng
University of Rochester
1 shared publication - Christopher T. Ritchlin
Center for Musculoskeletal Research University of Rochester Medical Center Rochester New York
1 shared publication - David G. Hicks
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA
1 shared publication - Edward M. Schwarz
Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York
1 shared publication - Kofi A. Mensah
Section of Rheumatology, Allergy, and Clinical Immunology, Yale University School of Medicine, New Haven, CT 06511, USA
1 shared publication
Latest Publications
- Open Access
- 10 October 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 27 (1) , 79-92
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Osteoclasts (OC) are bone‐resorbing, multinucleated cells that are generated via fusion of OC precursors (OCP). The frequency of OCP is elevated in patients with erosive inflammatory arthritis and metabolic bone diseases. Although many cytokines and cell surface receptors are known to participate in osteoclastogenesis, the molecular mechanisms underlying the regulation of this cellular transformation are poorly understood. Herein, we focused our studies on the dendritic cell‐specific transmembrane protein (DC‐STAMP), a seven‐pass transmembrane receptor‐like protein known to be essential for cell‐to‐cell fusion during osteoclastogenesis. We identified an immunoreceptor tyrosine‐based inhibitory motif (ITIM) in the cytoplasmic tail of DC‐STAMP, and developed an anti‐DC‐STAMP monoclonal antibody 1A2 that detected DC‐STAMP expression on human tumor giant cells, blocked OC formation in vitro, and distinguished four patterns of human PBMC with a positive correlation to OC potential. In freshly isolated monocytes, DC‐STAMPhigh cells produced a higher number of OC in culture than DC‐STAMPlow cells and the surface expression of DC‐STAMP gradually declined during osteoclastogenesis. Importantly, we showed that DC‐STAMP is phosphorylated on its tyrosine residues and physically interacts with SHP‐1 and CD16, an SH2‐domain‐containing tyrosine phosphatase and an ITAM‐associated protein, respectively. Taken together, these data show that DC‐STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC‐STAMP dynamically regulates cell signaling during osteoclastogenesis. © 2012 American Society for Bone and Mineral Research
- 10 October 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 27 (1) , 79-92
Open AccessRegulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Osteoclasts (OC) are bone‐resorbing, multinucleated cells that are generated via fusion of OC precursors (OCP). The frequency of OCP is elevated in patients with erosive inflammatory arthritis and metabolic bone diseases. Although many cytokines and cell surface receptors are known to participate in osteoclastogenesis, the molecular mechanisms underlying the regulation of this cellular transformation are poorly understood. Herein, we focused our studies on the dendritic cell‐specific transmembrane protein (DC‐STAMP), a seven‐pass transmembrane receptor‐like protein known to be essential for cell‐to‐cell fusion during osteoclastogenesis. We identified an immunoreceptor tyrosine‐based inhibitory motif (ITIM) in the cytoplasmic tail of DC‐STAMP, and developed an anti‐DC‐STAMP monoclonal antibody 1A2 that detected DC‐STAMP expression on human tumor giant cells, blocked OC formation in vitro, and distinguished four patterns of human PBMC with a positive correlation to OC potential. In freshly isolated monocytes, DC‐STAMPhigh cells produced a higher number of OC in culture than DC‐STAMPlow cells and the surface expression of DC‐STAMP gradually declined during osteoclastogenesis. Importantly, we showed that DC‐STAMP is phosphorylated on its tyrosine residues and physically interacts with SHP‐1 and CD16, an SH2‐domain‐containing tyrosine phosphatase and an ITAM‐associated protein, respectively. Taken together, these data show that DC‐STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC‐STAMP dynamically regulates cell signaling during osteoclastogenesis. © 2012 American Society for Bone and Mineral Research